Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Sera Prognostics ( (SERA) ) has shared an announcement.
Sera Prognostics announced the release of a new investor presentation and its participation in the upcoming J.P. Morgan Healthcare Conference. The release highlights the significance of preterm birth as a major health challenge and the company’s innovative approach using proteomics to predict and manage this condition. The PreTRM® Test, validated for use during weeks 18-20 of pregnancy, is emphasized as a critical tool in reducing the clinical and economic burdens of preterm birth, positioning Sera Prognostics as a leader in the prenatal diagnostics space.
More about Sera Prognostics
Sera Prognostics, Inc. operates in the healthcare industry, specializing in developing diagnostic tests for pregnancy-related complications. Its primary product, the PreTRM® Test, is designed to predict the risk of preterm birth and aims to transform pregnancy care by reducing uncertainties and improving outcomes.
YTD Price Performance: -16.81%
Average Trading Volume: 99,032
Technical Sentiment Consensus Rating: Hold
Current Market Cap: $234M
Learn more about SERA stock on TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue